Pfizer says booster dose of vaccine protects against omicron variant
Two doses of the Pfizer vaccine may not provide sufficient antibodies against the new variant, the company said.
A booster dose of the Pfizer-BioNTech Covid-19 vaccine appears to provide strong protection against the omicron variant, the companies announced Wednesday.
They said lab study results show a third dose of their vaccine provides a similar level of neutralizing antibodies to omicron, comparable to two doses against the original coronavirus and other variants that have emerged.
Blood samples from those who received only the primary series of the vaccine, on average, did see a 25-fold drop in antibodies against the new variant. That may indicate that two doses of the vaccine may not be sufficient to protect against infection with omicron, the companies said.
As the highly mutated omicron variant, first identified in South Africa, spreads around the globe, scientists are racing to determine how the available vaccines will work against it.
The companies said the results are preliminary. The findings were detailed in a press release, and the full data have not yet been made available for other scientists to scrutinize.
But lab studies are only one piece of the puzzle. Other data are also needed to determine whether a new vaccine is needed. Scientists need to understand transmissible the omicron variant is (early indications suggest it’s more contagious than the delta variant) as well as how sick it makes people (early data suggests the illness caused by the variant is milder).
The results from Pfizer-BioNTech are the first announced by vaccine makers.
According to the news release, blood samples were tested from people who had received either two or three doses of the vaccine. The samples were collected three weeks after the second dose or one month after the booster.
Tuesday, a South Africa research institute also released lab results on how the Pfizer vaccine fared against omicron, showing about a fortyfold reduction in vaccine-induced antibodies that could neutralize the new variant. That study didn’t look at booster shots, however.
On Nov. 25, the vaccine companies started to develop an omicron-specific vaccine. First batches of the vaccine can be produced and ready for delivery in about 100 days, depending on authorization from federal regulators, Pfizer has said.
Moderna and Johnson & Johnson are expected to release lab results from the omicron variant in the coming days. Academic research institutions are also looking into how well the vaccine works against omicron.